Management of unresectable urothelial cancer (UC) has been a clinical challenge for decades. While drug resistance is a key issue, precise understanding of biology of UC metastasis is another challenge for the improvement of treatment outcome of UC patients. Introduction of the cell biology concepts including epithelial-mesenchymal transition (EMT) and cancer stemness seems to explain UC metastasis. Molecular genetics based on gene expression profiling, next generation sequencing, and explosion of non-coding RNA world has opened the door to intrinsic molecular subtyping of UC. Next steps include, based on the recently accumulated understanding, the establishment of novel disease models representing UC metastasis in various experimental plat...
The processes of intraepithelial migration, intraluminal seeding, and field cancerization as models ...
Unmet needs in urothelial cancer management represent an important challenge in our effort to improv...
Epithelial-to-mesenchymal transition (EMT) has been implicated in the progression of bladder cancer....
AbstractManagement of unresectable urothelial cancer (UC) has been a clinical challenge for decades....
The current personalized oncology era has witnessed significant efforts to integrate clinical, patho...
Dmitriy Smolensky,1,2 Kusum Rathore,1 Maria Cekanova1,2 1Department of Small Animal Clinical Scienc...
Urinary bladder cancer (UBC) is a heterogeneous disease with highly variable clinical outcomes and r...
Urothelial bladder carcinoma (UBC) is an intricate malignancy with a variable natural history and cl...
Transitional cell carcinoma of the bladder is a common malignancy with an estimated 549 393 new case...
Approximately 70% to 80% of patients with urothelial carcinomas of the bladder are initially diagnos...
Urothelial carcinoma of the bladder comprises two long-recognized disease entities with distinct mol...
Metastatic urothelial cancer (UC) is associated with poor prognosis. In the first-line setting, plat...
Bladder cancer, one of the most prevalent malignancies worldwide, remains hard to classify due to a ...
Urinary bladder cancer (UBC) is the second most frequent malignancy of the urinary system and the ni...
Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths ...
The processes of intraepithelial migration, intraluminal seeding, and field cancerization as models ...
Unmet needs in urothelial cancer management represent an important challenge in our effort to improv...
Epithelial-to-mesenchymal transition (EMT) has been implicated in the progression of bladder cancer....
AbstractManagement of unresectable urothelial cancer (UC) has been a clinical challenge for decades....
The current personalized oncology era has witnessed significant efforts to integrate clinical, patho...
Dmitriy Smolensky,1,2 Kusum Rathore,1 Maria Cekanova1,2 1Department of Small Animal Clinical Scienc...
Urinary bladder cancer (UBC) is a heterogeneous disease with highly variable clinical outcomes and r...
Urothelial bladder carcinoma (UBC) is an intricate malignancy with a variable natural history and cl...
Transitional cell carcinoma of the bladder is a common malignancy with an estimated 549 393 new case...
Approximately 70% to 80% of patients with urothelial carcinomas of the bladder are initially diagnos...
Urothelial carcinoma of the bladder comprises two long-recognized disease entities with distinct mol...
Metastatic urothelial cancer (UC) is associated with poor prognosis. In the first-line setting, plat...
Bladder cancer, one of the most prevalent malignancies worldwide, remains hard to classify due to a ...
Urinary bladder cancer (UBC) is the second most frequent malignancy of the urinary system and the ni...
Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths ...
The processes of intraepithelial migration, intraluminal seeding, and field cancerization as models ...
Unmet needs in urothelial cancer management represent an important challenge in our effort to improv...
Epithelial-to-mesenchymal transition (EMT) has been implicated in the progression of bladder cancer....